Ficolin-1 is a recognition molecule of the lectin complement pathway. The ficolin-1 gene FCN1 is polymorphic, but the functional and clinical consequences are unknown.The concentration of ficolin-1 in plasma and FCN1 polymorphisms in positions À 1981 (rs2989727), À 791 (rs28909068), À 542 (rs10120023), À 271 (rs28909976), À 144 (rs10117466) and þ 7918 (rs1071583) were determined in 100 healthy individuals. FCN1 expression by isolated monocytes and granulocytes and ficolin-1 levels in monocyte culture supernatants were assessed in 21 FCN1-genotyped individuals. FCN1 polymorphisms were determined in a cohort of 251 patients with systemic inflammation. High ficolin-1 plasma levels were significantly associated with the minor alleles in position À 542 and À 144. These alleles were also significantly associated with high FCN1 mRNA expression. The level of ficolin-1 in culture supernatants was significantly higher in individuals homozygous for the minor alleles at positions À 542 and À 144. Homozygosity for these alleles was significantly associated with fatal outcome in patients with systemic inflammation. None of the other investigated polymorphisms were associated with FCN1 and ficolin-1 expression, concentration or disease outcome. Functional polymorphic sites in the promoter region of FCN1 regulate both the expression and synthesis of ficolin-1 and are associated with outcome in severe inflammation.
INTRODUCTION
An emerging role of the ficolins in innate immune defence has recently been appreciated. 1 Three ficolins, ficolin-1, -2 and -3 (also known as M-, L-and H-ficolin) have been identified in humans. These are encoded by the FCN1, FCN2 and FCN3 genes, respectively. Polymorphisms in the FCN2 and FCN3 genes are known to influence synthesis, function and structure of the corresponding proteins and disease associations have been described, but the influence of FCN1 polymorphisms are largely unknown.
2
FCN1 and FCN2 are genes located on chromosome 9 and FCN3 is sequestered on chromosome 1. All the three FCN genes have a similar locus organization encoding a short N-terminal cysteine region, followed by a collagen-like domain and a linker region, which is further connected to a C-terminal fibrinogen-like domain. FCN2 and FCN3 contain eight exons, whereas FCN1 has an additional exon in the collagen-like domain encoding four extra Gly-Xaa-Yaa repeats. 2 The ficolin polypeptide chains consist of 299-326 amino acids. Ficolin-1 and -2 are highly homologous molecules (80%), whereas the degree of homology with ficolin-3 is lower (48%). The similar locus organization of the FCN genes is reflected in the structure of the corresponding proteins. The proteins are assembled from 4-6 subunits, each subunit consisting of three identical polypeptides. Disulfide bonding further assembles these subunits into the characteristic higher oligomeric forms that resemble a bouquet. 3 The C-terminal end of the molecule, the globular fibrinogen-like domain, is responsible for ligand recognition. [3] [4] [5] Although the ficolins share a common preference for acetylated compounds, each ficolin displays distinct ligand specificities. Ficolin-2 binds to a wide range of pathogens, such as bacteria, fungi and viruses, whereas only a few bacterial ligands have been identified for ficolin-3.
1 Both ficolin-2 and -3 have been shown to bind to apoptotic cells. [6] [7] [8] Ficolin-1 has a preference for sialic acid 9 and binds to sialicacid-containing structures present on living monocytes and granulocytes. 10 A highly conserved cysteine residue in the collagen-like domain enables all three ficolins to form complexes with the mannosebinding lectin/ficolin-associated serine proteases named MASPs and hence to activate the complement cascade through the lectin pathway. 1 However, the potential to activate complement differs among the ficolins, ficolin-3 being the most potent, ficolin-2 intermediate and ficolin-1 displaying least complement activation potential. 11 Each FCN gene exhibits a unique expression profile.
11 FCN2 expression is limited to hepatocytes and is secreted to the blood stream. [12] [13] [14] FCN3 is expressed both in the liver and lungs, but the FCN3 expression in the alveolar tissue exceeds the hepatic expression. 11 In accordance, ficolin-3 is found in plasma and bronchoalveolar lavage fluid. 15 Lower FCN3 expression is found in heart, kidney, spleen, pancreas and placenta.
11
FCN1 is predominantly expressed by cells derived from the myeloid lineage in the bone marrow and is found in the peripheral circulation in monocytes and granulocytes, but not in cells of lymphoid origin. [16] [17] [18] [19] In addition, ficolin-1 may be expressed in the lungs. 20 Both neutrophils and monocytes secrete ficolin-1 to the surroundings where it may have a role in local immune defence. 10, 17, 18, 21 The FCN1 gene is well conserved between invertebrates, mouse and human, suggesting crucial and fundamental roles of ficolin-1.
2,22
Several polymorphisms have been described both in the promoter and coding region when the FCN1 gene has been thoroughly sequenced. 13, 23 To date, no or only limited information exists whether variations in FCN1 influence the expression, the synthesis or plasma level of ficolin-1 and whether such may be of clinical importance. We therefore wanted to determine the genetic impact of the FCN1 polymorphisms described in Caucasians on the FCN1 gene expression, ficolin-1 synthesis and plasma level of ficolin-1. Furthermore, based on the putative role of ficolin-1 in host defence and inflammation, we hypothesized that functional FCN1 variant alleles may have an impact on outcome in patients with systemic inflammatory response syndrome (SIRS) and sepsis.
RESULTS
Establishing a ficolin-1-specific enzyme-linked immunosorbent assay (ELISA) The specificity of the ficolin-1 ELISA was assessed by determining the ficolin-1 level in EDTA plasma samples before and after the removal of ficolin-2. No reduction was observed in the optical density values obtained in the ficolin-1 ELISAs (Figure 1 ). Similarly, adding recombinant ficolin (rficolin)-2 to the depleted plasma samples did not change the read-out of the ficolin-1 ELISA. Thus, the ficolin-1 ELISA demonstrated no cross-reactivity with ficolin-2.
Plasma levels of ficolin-1
The concentration of ficolin-1 ranged 0.01-1.89 mg ml À 1 with a median concentration of 0.3 mg ml À 1 determined in 100 Danish blood donors (Figure 2 ). No correlation was observed with gender, age or with the levels of ficolin-2 (data not shown). It has been shown that neutrophils might be the primary source of ficolin-1 in the blood, 21 thus we determined the level of neutrophil gelatinase-associated lipocalin (NGAL) and gelatinase, which reflects the pool of circulating neutrophils. 24, 25 No correlation was observed with either NGAL or gelatinase (data not shown).
Validation of the ficolin-1 plasma concentration To ensure the validity of the newly established ficolin-1 ELISA, the ficolin-1 concentration was determined in plasma samples from 21 additional donors and the levels were compared with the concentrations obtained with a commercially available ficolin-1 ELISA kit (E90786Hu; Uscn Life Science Inc, Whhan, China). The median ficolin-1 concentration observed with the newly established ELISA in the 21 additional donors was 0.37 mg ml À 1 compared with 0.27 mg ml À 1 in the purchased ELISA kit. Moreover, the ficolin-1 concentrations correlated significantly between the two methods (Spearman's r ¼ 0.7532, Po0.0001) (data not shown). When the samples were depleted for ficolin-2 as described in our original report showing ficolin-1 in plasma, 10 which involved prolonged incubation of anti-ficolin-2 antibodies with protein A beads, we observed a median concentration of 0.09 mg ml À 1 using our new in-house assay and 0.07 mg ml À 1 for the commercial assay (data not shown).
Genotyping of the FCN1
To establish whether polymorphisms in the FCN1 gene influences the level of synthesis of ficolin-1, we genotyped 100 blood donors for the known polymorphisms at positions: FCN1 À 1981 (rs2989727), À 791 (rs28909068), À 542 (rs10120023), À 271 (rs28909976), À 144 (rs10117466) and þ 7918 (rs1071583) ( Table 1 ). All the polymorphisms adhered to the Hardy-Weinberg expectations and the allele frequencies obtained were in good agreement with the allele frequencies observed before. 13, 23 As previously reported, the promoter polymorphism at position À 1981 and the polymorphism in position þ 7918 in exon 9 were near complete linkage disequilibrium (r 2 ¼ 0.98, Po0.0001); 26 the major allele from both polymorphisms segregated together in all individuals apart from one ( Figure 3) . Further, linkage disequilibrium, although to a lesser degree (r 2 ¼ 0.71, Po0.001), was observed for À 542 with À 144. Linkage disequilibrium between any of the other polymorphisms was not observed.
FCN1 variation associated with the ficolin-1 plasma level We investigated the association of the FCN1 polymorphisms with the ficolin-1 plasma concentration in the 100 blood donors. Two of the polymorphisms in the promoter, FCN1 À 542 and À 144, were significantly associated with the level of ficolin-1 in EDTA plasma (P ¼ 0.0021 and 0.0057 (Kruskal-Wallis), respectively) (Figures 4a  and b) . Homozygosity for the minor allele in both FCN1 À 542 and À 144, A/A and A/A, respectively, was associated with high levels of ficolin-1. The level of ficolin-1 was higher in individuals homozygous for the major allele in both positions, for example, the haplotype À 542 A and À 144 A (n ¼ 36) when compared with those homozygous for the minor allele GC at both positions (n ¼ 11) (P ¼ 0.066 (Mann-Whitney)) (Figure 4c ). In addition, association of ficolin-1 level with the low frequent polymorphism FCN1-791 (minor allele frequency pB ¼ 0.045) was observed (data not shown). No significant association was seen with any of the other polymorphisms (FCN1 À 1981, À 271 and þ 7918, P40.1289) (data not shown). The impact of genetic variation on ficolin-1 synthesis in monocytes To investigate the influence of FCN1 polymorphisms on ficolin-1 release from monocytes, 53 staff members were screened for homozygosity on positions FCN À 542 and À 144. We attained 21 individuals distributed as followed: 16 individuals that were homozygous for the haplotype GC (that is, G/G and C/C at both positions) and 5 individuals with the homozygote haplotype AA (that is, A/A and A/A at both positions) at positions À 542 and À 144, respectively. From these individuals, monocytes were isolated and cultured for 2 days. The supernatant was harvested by adding EDTA to the culture and the amount of membrane released ficolin-1, and the secreted ficolin-1 was determined using the ficolin-1-specific ELISA. The level of ficolin-1 released to the culture supernatant was significantly associated with the À 542 and À 144 genotypes, as monocytes from individuals with the AA haplotype released significantly more ficolin-1 to the media compared with the release from monocytes isolated from individuals with the GC haplotype (P ¼ 0.0057 (Mann-Whitney)) ( Figure 6 ).
Genotype distribution in patients with SIRS/sepsis Out of 251 patients with SIRS who were enrolled in this study, 64 patients had SIRS without infection, 26 fulfilled the criteria for sepsis, 94 for severe sepsis and 63 for septic shock. All the polymorphisms adhered to the Hardy-Weinberg expectations except for FCN1 À 542 that deviated slightly (w 2 ¼ 7.56, Po0.01). The allele distribution of these two polymorphisms, À 791 and À 542, in patients with SIRS/sepsis diverged significantly from the allele distribution in blood donors (w 2 ¼ 8.42, P ¼ 0.004 and w 2 ¼ 7.00, P ¼ 0.008, respectively) ( Table 1) . No dissimilarity in the allele frequency for À 1981, À 271, À 144 and þ 7918 was observed when comparing the SIRS/sepsis patients with the blood donors nor was there any significant difference observed when comparing patients with SIRS, sepsis, severe sepsis and septic shock (P40.122). However, homozygosity for the minor FCN1 À 542 A and À 144 A alleles was significantly associated with fatal outcome compared with patients heterozygous or homozygous for the major alleles (G or C, respectively) (log rank: P ¼ 0.0395 and 0.0008, respectively) ( Figures 7a and b) at the 360 days follow-up period. Further, the significant association persisted when assessing individual homozygous haplotype À 542 and À 144 GC or AA (log rank: P ¼ 0.0024) (Figure 7c ). Cox regression analysis showed that the increased mortality rate of the minor alleles was independent of sex and gender (P ¼ 0.0254, 0.0019 and 0.0066, respectively). No association with fatal outcome was observed for the other polymorphisms at positions FCN1 À 1981, À 791, À 271 and þ 7918 (P40.2325). Plasma was not eligible for this part of the study.
Prediction of putative transcription-factor-binding sites As both FCN1 À 542 and À 144 influences the level of the gene expression and synthesis of ficolin-1, we investigated the adjacent sequences for known transcription-factor-binding motifs. Short sequences (21 base pair) containing the polymorphisms were uploaded to Transcription Element Search System, a web tool for predicting transcription-factor-binding sites (www.cbil.upenn.edu/ cgi-bin/tess/tess). The search revealed that the FCN1 À 542 A allele is located within the theoretically binding motif (AAATG) for YY1. YY1 is a transcription factor known to bind to core elements in the promoter for the gene encoding granulocyte/macrophage colonystimulating factor (GM-CSF), enhancing the gene expression. 27 
DISCUSSION
In this study, we established a specific quantitative ficolin-1 ELISA. The normal range of ficolin-1 in EDTA plasma was found to be 0.01-1.89 mg ml À 1 with a median ficolin-1 concentration of 0.30 mg ml À 1 . To validate the results, we correlated the ficolin-1 concentration in the new assay with the concentration measured in a commercially available assay. The ficolin-1 levels measured in both assays were almost identical and a highly significant correlation was observed. Thus, it appears that the plasma ficolin-1 levels measured in the new assay are reliable. We previously reported the median ficolin-1 concentration to be 0.06 mg ml À 1 in a small study comprising eight normal individuals using an assay where ficolin-2 had to be depleted prior to the analysis due to a cross-reactive capture antibody. 10 Using the same procedure, we depleted samples for ficolin-2 prior to ficolin-1 assessment in both the new ficolin-1 assay and the commercial one. We observed that the concentration of ficolin-1 was approximately four-fold decreased compared with native plasma compatible with the concentrations observed in our original article. 10 However, when we depleted ficolin-2 using a modified technique as reported here, no decrease was observed. Thus, the concentrations of ficolin-1 described in the original report 10 appears to be too low as some ficolin-1 may have been lost during the sample handling. It has recently been reported that the median ficolin-1 concentration in serum in another group of healthy donors was 1.07 mg ml À 1 with a range 0.28-4.05 mg ml À 1 using a different assay. 28 However, ficolin-1 may leak from damaged cells and has been shown to be released from the monocytes and granulocytes in the presence of calcium chelators like EDTA. 19, 29 These observations may account for the discrepancy between the obtained ficolin-1 measurements; thus, the actual free plasma concentration or fraction is difficult to ascertain at present. The plasma concentrations we observed were validated in two independent assays giving support to the view that the free ficolin-1 concentration in plasma is much lower than the levels observed for ficolin-2 and -3. 14,30 Nevertheless, no internationally established standard of ficolin-1 exists that could be used to clarify the differences between the various studies, which therefore are urgently needed.
It has been shown that the ficolin-1 plasma concentration may reflect the granulocyte count in the circulation in children with various forms of cancers. 31 We did not measure the granulocyte count in our donors, but in order to circumvent this, we used the plasma concentration of NGAL and gelatinase as surrogate markers for the granulocyte count, but found no correlation with the ficolin-1 concentration. The plasma concentration of NGAL and gelatinase has previously been shown to closely mirror the granulocyte count in healthy adults. 24, 25 Thus, the interindividual fluctuation in ficolin-1 concentrations in normal individuals may not within certain limits be dependent on the actual granulocyte count.
We used the ficolin-1 assay to establish whether polymorphisms in the FCN1 gene could explain the variation in the plasma concentration of ficolin-1. Our results show that the major alleles of the two FCN1 polymorphisms at position À 542 (rs10120023) and À 144 (rs10117466) were significantly associated with low ficolin-1 levels, whereas the presence of the minor allele in both position was associated with high ficolin-1 concentration. These alleles are present in strong linkage disequilibrium (r 2 ¼ 0.71) in healthy individuals. In another group of individuals, we determined the amount of ficolin-1 secreted and surfacereleased ficolin-1 in monocyte cultures harvested after 2 days and found the same association between the protein released and FCN1 polymorphisms as in plasma. Moreover, the FCN1 mRNA expression level was also associated with the same polymorphic variants. Only in the monocytes, a gene-dose-dependent association was observed, whereas this was not clearly apparent with the ficolin-1 plasma concentration and FCN1 expression profile from the granulocytes. The reason for this is unknown, but could indicate that different regulatory factors are dependent on the actual site of expression and synthesis. Taken together, these results show that the variation of ficolin-1 expression, synthesis and levels are associated with variation in the promoter region of FCN1. We cannot state firmly based on these observations that these polymorphisms are causal for the difference in the observed expression and synthesis of FCN1 and ficolin-1, respectively. They may be tagging polymorphisms in strong linkage disequilibrium with causal cis-acting variations. However, it is of notable interest that when we used in silico analysis we found that the minor À 542 allele was predicted to lie within the YY1 transcription-factor-binding site. Several YY1-binding sites have been identified in the promoter to the gene encoding GM-CSF, and YY1 has been shown to enhance gene expression. 27 If this is true, the À 542 minor allele may facilitate YY1 binding, causing amplified gene expression. Similarly, the À 144 minor allele may discriminate binding to other unknown transcription factors. Thus, they may be considered as gain of function polymorphisms. It should be noted that both of these polymorphisms are relatively rare in Sub Saharan Africans and the Japanese population supporting such a notion that they have gained momentum in the Caucasian population due to selective advantages that have increased the frequency. 23 None of the other investigated polymorphisms were associated with significant FCN1 expression and ficolin-1 synthesis except that the low frequent polymorphism at position À 791 (rs28909068) (minor allele frequency pB ¼ 0.045) was weakly associated with the ficolin-1 plasma level. The primary ligand of ficolin-1 has been shown to be sialic acid, which is present on different pathogens such as capsulated group B Streptococci. 9, 29 Nevertheless, the role of ficolin-1 in innate immunity is an enigma because ficolin-1 is tethered to sialic acid on living cell cells via its fibrinogen-like pattern recognition domain. 19 Sialic acid is typically present on the surface of normal cells. 29 Moreover, ficolin-1 may to some degree activate the complement system via the lectin pathway. 11, 18, 32 Thus, ficolin-1 appears to have the capacity to recognize both foreign and self structures and mediate complement activation.
This puzzle stimulated us to investigate whether the FCN1 polymorphisms could be associated with development of the SIRS and sepsis as well as outcome. Our results show that the FCN1 polymorphisms could not be used as predictive markers for development of SIRS and sepsis in this well-defined historical cohort of patients admitted to an intense care unit, 33 but the frequency of the alleles at position À 791 and À 542 deviated slightly between patients and controls. Nevertheless, a robust significant association was observed between the À 542 and À 144 minor alleles, as well as the minor À 542/ À 144 haplotype and decreased survival, whereas no association was observed for the other investigated alleles. The association was independent of possible confounding factors such as age and gender. Previously polymorphisms in the gene encoding mannose-binding lectin (MBL2) have been investigated in this cohort. 33 Thus, we investigated whether a synergistic effect between the MBL2 and FCN1 systems might be apparent. However, no such interaction was observed (data not shown). These observations clearly designate ficolin-1 as an important molecule of innate immune defence and that variation in the FCN1 gene may contribute to the inter-individual reaction to severe inflammation. The fact that the FCN1 risk alleles are associated with increased synthesis of ficolin-1 is challenging and suggests a dual role of the molecule conferring both advantages and disadvantages in host defence. In this regard, it is interesting that excessive activation of complement, which takes place in SIRS and sepsis, has been shown to be associated with fatal outcome. 34 Moreover, genetic-dependent complement deficiency and depletion have been shown to be beneficial in animal models of complement-dependent inflammation. 35 It may be assumed that ficolin-1 has both a direct antimicrobial role and a modulating effect on the inflammatory response, which in the case of severe inflammation may be a disadvantage. Nevertheless, an observation made in a single centre study should be interpreted with caution. Thus, to establish the full effect ficolin-1 may have on severe inflammation, these findings need to be replicated in other populations, as well as in settings with different microbial regimens and clinical surveillance regimes.
In conclusion, we have shown that expression and synthesis of ficolin-1 is clearly associated with two polymorphisms in the promoter region of FCN1. The same polymorphisms were associated with decreased survival in a cohort of patient with SIRS and sepsis. These results strongly suggest that ficolin-1 is an important molecule in innate immune defence and may have a central role in the effector functions mediated by granulocytes and monocytes.
MATERIALS AND METHODS

Donor samples
Peripheral venous blood samples drawn in EDTA-containing glass were obtained with informed consent from 121 unrelated adult Danish blood donors. Additionally, 53 blood heparin plasma samples were collected from unrelated healthy staff members.
Patients
From a previously well-described cohort of 271 patients, DNA from 251 patients unrelated Danes of Caucasian descent (range: 18-88 years) admitted to the academic, multidisciplinary intensive care unit at Glostrup University Hospital, in Copenhagen, Denmark, were eligible. The clinical data have been described in detail. 33, 36 The study was prospective with a Mendelian randomization design. All the patients met the criteria for SIRS, sepsis, severe sepsis or septic shock as outlined by Bone et al. 37 Sample preparation Samples for plasma preparation were processed within 3 h and stored at À 80 1C. Separate glasses were used for cell isolation, DNA isolation and plasma preparation.
Ethics
The study was approved by the local ethics committee (record number KA 96097). rficolins rficolin-1 was produced as previously described for ficolin-2.
3 Briefly, the FCN1 gene was amplified from liver cDNA and tagged-C-terminal with a penta-His. This construct was cloned into an expression vector and transfected into a Chinese hamster ovary cell line, DG44. Subsequently, ficolin-1 was purified from the cell supernatant on a Ni-NTA column (Qiagen Nordic, West Sussex, UK). Using the same procedure, rficolin-2 was also produced and used as specificity control.
Generation of monoclonal anti-ficolin-1 antibodies
Female NMRIxBalb/c F1-mice were immunized subcutaneously with 25 mg of rficolin-1 adsorbed to Al(OH) 3 and mixed in 1:1 ratio with Freund's incomplete adjuvant. After three immunizations with 2-weeks interval, the mice received an intravenous injection with 25 mg of antigen administered with adrenalin. After 4 days, the spleen was isolated and a single-cell suspension of spleen cells was prepared. Fusion was performed essentially as described by Reading. 38 Ten days after fusion, supernatants from wells with cell growth were analyzed in ELISA with wells coated with rficolin-1. Positive wells were cloned by dilution. The clones were analyzed with respect to cross-reactivity of the highly homologous ficolin-2 as previously described.
14 Out of 20 positive clones, 4 clones did not also react with rficolin-2 coated in ELISA wells. One of these clones, FCN165, was chosen to be used as capture antibody in a quantitative ficolin-1-specific ELISA. The antibody produced by the FCN165 clone was of the isotype IgG1 (IsoQuick kit, ISOQ25; Sigma Aldrich, Broendby, Denmark).
Ficolin-1-specific ELISA
The ficolin-1-specific monoclonal antibody (FCN165) was coated at 1 mg ml À 1 in microtiter wells in phosphate-buffered saline (PBS) overnight at 4 1C. EDTA plasma samples (diluted 1:10) or culture supernatant (in a two-fold dilution serie) in PBS-T (PBS with 0.05% Tween-20 (15797-1; VWR International, Herlev, Denmark)) containing 5 mM EDTA were incubated 3 h shaking followed by incubation overnight with rabbit-poly-clonal anti-human ficolin-1 (HP9039; Hycult Biotech) at a final concentration of 2 mg ml À 1 diluted in PBS-T. Antirabbit-horseradish peroxidase (NA09340V, GE antibodies (GE Healthcare, Little Chalfont, UK)) was added and incubated for 2 h. Finally, the plated were developed with a substrate solution (3 o-phenylenediamine tablets in 12 ml dH 2 O and 5 ml H 2 O 3 ) and stopped by adding 50 ml 1M H 2 SO 4 and read at optical density 490 nm. A serial dilution of supernatant from cultivated monocytes was used as calibrator. The concentration of the calibrator was established by analysing dilutions of the culture supernatant in parallel with a serial dilution of known concentrations of rficolin-1.
In order to correlate the concentration in the new assay with an established assay, we purchased a commercial ficolin-1 ELISA kit (E90786Hu, Uscn Life Science Inc) and tested additional EDTA samples from 21 healthy donors. The commercial assay was used according to the manufacturer's guidelines.
Depletion of ficolin-2 in plasma samples
A total of 10 mg of the monoclonal anti-ficolin-2 FCN219 antibody was absorbed to 100 ml protein A sepharose beads (GE17-5138-02) overnight at 4 1C. The beads were washed trice in PBS-T and added to EDTA plasma samples diluted 1:10 in PBS-T in a total volume of 1 ml. Following sample incubation for 3 h head-over-head, the beads were pelleted by centrifugation. Aliquots of the depleted samples were spiked with up to 1 mg ml
rficolin-2 and all aliquots were analyzed both in the ficolin-2 and -1 ELISA.
FCN1 expression and disease L Munthe-Fog et al
In addition, we depleted and tested 21 EDTA samples for ficolin-2 according to the method described by Honoré et al.
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Ficolin-2, NGAL and gelatinase ELISA Measurement of ficolin-2, NGAL and gelatinase was conducted as described. 14, 24, 25 Briefly, EDTA plasma samples were applied to microtiter wells coated with either anti-ficolin-2 antibody, rabbit-anti-NGAL or rabbitanti-gelatinase, respectively. Following incubation, the wells were washed, and bound ficolin-2, NGAL or gelatinase was detected using biotinylated anti-ficolin-2 antibody, anti-NGAL or anti-gelatinase, respectively, and subsequently with horseradish peroxidase-conjugated streptavidin. The plates were developed with substrate solution and the optical density value was determined at 490 nm.
Isolation of monocytes and granulocytes
Monocytes and granulocytes were isolated using EasySep (cat. no 18088 and 18083, respectively; StemCell Technologies, Grenoble, France) on the RoboSep machine (cat. no 20000; StemCell Technologies). From the dry cells, mRNA was obtained using the KingFisher technology (Thermo Scientific, Soeborg, Denmark). Monocytes for cultivation were isolated from blood collected in heparin glasses obtained from staff members. The monocytes were resuspended in 1 ml AIM-V (Invitrogen, Naerum, Denmark) þ 10% fetal bovine serum containing l-glutamine, streptomycin sulphate, gentamicin sulphate (Invitrogen) and cultured in a concentration of 2 Â 10 6 cells per well in a total volume of 250 ml. The supernatant was harvested on day 2 by adding 10 mM EDTA to the wells 10 min prior to centrifugation.
DNA preparation
Genomic DNA was prepared from each blood sample by automated DNA purification (Maxwell 16 System, AS1010; Promega, Stockholm, Sweden) according to the manufacturer's guidelines.
Sequencing
Each sequence was PCR amplified using a single primer set with a 5 0 -T7 sequence (5'-TAATACGACTCACTATAGGG-3') ( Table 2) . PCR amplifications were carried out in 12 ml volumes containing: B20 ng genomic DNA, 0.25 mM of each primer, 2.5 mM MgCl 2 , 0.2 mM dNTP, 50 mM KCl, 10 mM Tris-HCl, pH 8.4 and 0.4 U of Platinum Taq DNA polymerase (Invitrogen). The PCR reactions were performed at the following cycling parameters: 2 min at 94 1C, 35 Â (30 s at 94 1C, 60 s at 58 1C and 60 s at 72 1C) and 5 min at 72 1C. The PCR product was Sanger-sequenced using a biotinylated T7 primer (0.25 mM) with the ABI BigDye cycle sequencing terminator kit (Applied Biosystems, Naerum, Denmark). Sequence reactions were vacuum purified using Streptavidin Sepharose High Performance beads (17-5113-01; GE Healthcare) and sequence analysis was performed on an ABI Prism 3100 Genetic Analyser (Applied Biosystems). The resulting DNA sequences were aligned using BioEdit software (Ibis Biosciences, Carlsbad, CA, USA) and DNA polymorphisms were confirmed visually from sequence electropherograms.
Allelic discrimination using TaqMan genotyping assay
To each allele-specific reaction, 12.5 ml TaqMan Universal PCR Master Mix, 0.63 ml 40Â TaqMan genotyping assay (C_2674032_10 (FCN1-1981) or C_1819018_1 (FCN1 þ 7918) (Applied Biosystem) and 20 ng genomic DNA diluted in 11.9 ml dH 2 O was added on a Termofast 96-wells 0.2 ml PCR plate (ABgene), which was heat sealed using Optical Caps (ABgene Thermo Scientific, Soeborg, Denmark). On each plate (running 44 samples), four controls were added; two no-template controls and two allelic controls containing either A or B allele. PCR was performed under the following conditions: 10 min at 95 1C, 40 Â (15 s at 92 1C and 1 min at 60 1C). Results were analyzed on ABI PRISM 7700 Sequence Detector machine with the SDS software v1.9 (Applied Biosystem), using the allele discrimination plate read function to detect the end-point fluorescence in each well.
Allelic discrimination using minor groove binder probe assay The patients were genotyped using TaqMan MGB probe assay (TaqMan MGB assay, Applied Biosystems). To each allele-specific reaction (for primer and probe sequences see Table 3 ), 12.5 ml TaqMan Universal PCR Master Mix, 0.6 ml 40 Â Custom Assay Mix and 20 ng genomic DNA diluted in 11.9 ml dH 2 O was added on a termofast 96-well 0.2 ml PCR plate that was sealed using optical caps (ABgene). Four controls were added on each plate (running 44 samples): two no-template controls and two allelic controls containing DNA with either A or B allele. PCR was performed under the following conditions: 10 min at 95 1C, 40 Â (15 s at 92 1C and 1 min at 60 1C). Results were analyzed on ABI PRISM 7700 Sequence Detection platform using the SDS software v1.9 (Applied Biosystem).
Identification of polymorphisms
All the polymorphisms are registered in the NCBI's dbSNP database by the accession numbers (rs) given in Table 1 .
Real-time quantitative PCR
FCN1 expression was determined using (Hs00157572_m1, Applied Biosystems) and glyceraldehyde-3-phosphate-dehydrogenase (Hs99999905_m1, Applied Biosystems) was used as an internal standard. In 20 ml volume, cDNA was added to TaqMan universal PCR master mix (Applied Biosystems) containing TaqMan gene expression assay and amplification (2 min at 50 1C, 10 min at 95 1C and 50 Â (15 s at 95 1C and 1 min at 60 1C)) was conducted on ABI Prism 7700 sequence detector (Applied Biosystem).
Relative mRNA values were calculated using following formula: 1/(2 DCt ) Â 1000.
Statistical methods
Hardy-Weinberg was analyzed using simple gene counting and the Chi-square test with Yates' correction. The inferred haplotypes and LD, expressed as r 2 were estimated using the SNPAlyze program version 4.0 (Dynacom, Yokohama, Japan) and the software platform SHEsis 39 Nonparametric Kruskall-Wallis or Mann-Whitney for unpaired group comparison was used to assess the genotypic impact on ficolin-1 levels and FCN1 expression, and Spearman's rank was used when correlating plasma and 
